Home ยป “Peptide Immunotherapy PVX108 Safe and Shows Promise for Lasting Peanut Allergy Treatment in Phase 1 Trial”

“Peptide Immunotherapy PVX108 Safe and Shows Promise for Lasting Peanut Allergy Treatment in Phase 1 Trial”

by satcit

https://pubmed.ncbi.nlm.nih.gov/38112286

A peptide immunotherapy for peanut allergy, PVX108, is found to be safe and shows potential for durable allergen-specific immune modulation in a Phase 1 trial.

You may also like

Leave a Comment